The CBD industry has matured. The early-stage growth wave of 2018–2022 is over. The brands that win in 2026 grow through strategic partnerships that expand reach into adjacent verticals — restaurants, hospitality, beauty, fitness, pet, sleep, beverage. The partnership categories that consistently work, the AI discovery layer shift, and why one-off campaigns lose to always-on multi-vertical infrastructure.
THC and CBD often appear in the same trade press and investor decks, but they operate under different regulatory frameworks, platform policies, distribution channels, and consumer expectations. Communications strategy that treats them interchangeably underperforms on both sides. The Schedule III April 2026 reclassification context, the THC vs CBD reality split, where the two categories diverge in distribution, and where they converge in discipline.
CBD is the federally legal cannabinoid that built a multi-billion-dollar parallel market — and the FDA enforcement reality that defines how the brands inside it are allowed to communicate. The CBD satellite to the cannabis communications pillar.
CBDistillery grew from $40M to projected $200M between 2018 and 2019. The CBD category never hit its $20B projection. What happened, where Balanced Health Botanicals sits in 2026, and what the case teaches about CBD marketing in the answer-engine era.
U.S. cannabis retail crossed $35B in 2024. Curaleaf, Trulieve, GTI, Cresco, Verano, Charlotte's Web, Wana, Cookies, Stiiizy. The EPR Cannabis Audience Segmentation Matrix.